STAT+: Five biotech updates to read after ESMO this weekend
Moderna and Merck are racing to submit their personalized cancer vaccine for FDA approval, expected in 2027, according to Moderna CEO Stéphane Bancel.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.